Home World News FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder... World News FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 205 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 Talking With Your Doctor About Negative Emotions During Cancer November 3, 2020 Why people and culture matter in research August 10, 2021 The Mediterranean Diet October 30, 2020 Load more HOT NEWS Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... The Taylor Family Foundation gives £2.1m to support head and neck... Tips On Staying Cool During a Heat Wave
